共 86 条
- [1] Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial [J]. LANCET INFECTIOUS DISEASES, 2019, 19 (03) : 253 - 264
- [2] Abrams D, 2009, NEW ENGL J MED, V361, P1548, DOI 10.1056/NEJMoa0903175
- [3] [Anonymous], 2006, PREZ DAR
- [4] [Anonymous], 2013, TIVICAY DOL
- [5] [Anonymous], 2019, TOP ANTIVIR MED
- [6] [Anonymous], 2011, ED RILP
- [7] [Anonymous], GUIDELINES USE ANTIR
- [8] [Anonymous], 2015, PREZCOBIX DAR COB
- [10] Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial [J]. LANCET INFECTIOUS DISEASES, 2015, 15 (07) : 785 - 792